Evidence map›Paper›PMID 38609998›Full record

ArticleJournal of nanobiotechnology2024

Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19.

Jia-You Fang, Kuo-Yen Huang, Tong-Hong Wang, Zih-Chan Lin, Chin-Chuan Chen, Sui-Yuan Chang, En-Li Chen, Tai-Ling Chao, Shuenn-Chen Yang, Pan-Chyr Yang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Recent advances in TAM mechanisms in lung diseases.Journal of translational medicine · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Jia-You Fang *Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Taoyuan, Taiwan.
Kuo-Yen Huang *Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Tong-Hong Wang *Graduate Institute of Natural Products, Chang Gung University, Taoyuan, Taiwan.
Zih-Chan LinChronic Diseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Chiayi, Taiwan.
Chin-Chuan ChenGraduate Institute of Natural Products, Chang Gung University, Taoyuan, Taiwan.
Sui-Yuan ChangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
En-Li ChenGraduate Institute of Natural Products, Chang Gung University, Taoyuan, Taiwan.
Tai-Ling ChaoDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Shuenn-Chen YangInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Pan-Chyr YangInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. pcyang@ntu.edu.tw.
Chi-Yuan ChenGraduate Institute of Health Industry Technology, Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Taoyuan, Taiwan. cychen@mail.cgust.edu.tw.
Chang Gung University · TWInstitute of Biomedical Sciences, Academia Sinica · TWNational Taiwan University · TWChang Gung Memorial Hospital · TWChang Gung University of Science and Technology · TWNational Taiwan University of Science and Technology · TW

Funding

Chang Gung Memorial Hospital CMRPF1L0052Chang Gung University of Science and Technology ZRRPF3M0091Ministry of Science and Technology of Taiwan MOST 111-2320-B-255-003National Science and Technology Council NSTC 111-2124-M-002 -010
6 · The paper itself

Abstract

introductionAngiotensin-converting enzyme 2 (ACE2) and AXL tyrosine kinase receptor are known to be involved in the SARS-CoV-2 entry of the host cell. Therefore, targeting ACE2 and AXL should be an effective strategy to inhibit virus entry into cells. However, developing agents that can simultaneously target ACE2 and AXL remains a formidable task. The natural compound quercetin has been shown to inhibit AXL expression. MATERIALS AND

methodsIn this study, we employed PLGA nanoparticles to prepare nanoparticles encapsulated with quercetin, coated with ACE2-containing cell membranes, or encapsulated with quercetin and then coated with ACE-2-containing cell membranes. These nanoparticles were tested for their abilities to neutralize or inhibit viral infection.

resultsOur data showed that nanoparticles encapsulated with quercetin and then coated with ACE2-containing cell membrane inhibited the expression of AXL without causing cytotoxic activity. Nanoparticles incorporated with both quercetin and ACE2-containing cell membrane were found to be able to neutralize pseudo virus infection and were more effective than free quercetin and nanoparticles encapsulated with quercetin at inhibition of pseudo virus and SARS-CoV-2 infection.

conclusionsWe have shown that the biomimetic nanoparticles incorporated with both ACE-2 membrane and quercetin showed the most antiviral activity and may be further explored for clinical application.

Indexed as

COVID-19NanoparticlesAngiotensin-Converting Enzyme 2HumansQuercetinSARS-CoV-2Angiotensin-Converting Enzyme 2QuercetinACE2AXLCOVID-19NanoparticlesQuercetin

Identifiers

PMID38609998
PMCPMC11015574
OpenAlexW4394734735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.